- Engage with senior executives from prominent life sciences companies, CROs and healthcare providers
- 75% of attendees in 2023 had a job title of 'Head of' or above, so true decision-makers will be on site
- Schedule 1-to-1 meetings with leaders in the online event community
- Establish new relationships and strengthen ties at our evening drinks reception
- FT editors and other global press outlets will be there
US Pharma and Biotech Summit
2024 is a pivotal year for US healthcare, in particular for the pharma and biotech industries. A presidential election will influence crucial policies on drug pricing and health financing for years to come. AI technologies are evolving from buzzwords to making an impact in drug R&D. Pharma is facing a huge patent cliff. And the biotech market appears to be pulling out of a slump just as the US economy executes the soft landing policymakers have hoped for.
The Financial Times US Pharma and Biotech Summit returns to New York in May 2024, partnered with Endpoints News for the first time. The event will gather biopharma leaders, regulators, investors and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country.
Join us to learn how the new market cycle will finance the next period of investing in innovation. Debate the dueling approaches to the US life expectancy crisis. Hear how artificial intelligence is splitting into two technological camps. And learn how drug makers, tech startups and insurers are fighting it out to redefine their relationship with patients.
Key themes
Investment
Where are investors in American life sciences putting their money? How is competitiveness across the biopharma industry evolving? What challenges do biotech leaders face in negotiating partnerships and potentially acquisition?
Innovation
How far has the application of AI in life sciences come in the last year and what breakthroughs could be coming? What new skills and solutions are young pharma professionals bringing to workforces and how are they driving innovation?
Policy
What should the biopharma industry expect in terms of economic policy, and how will those macro dynamics affect business and investment trends? What could be the impact of a pivotal presidential election on the industry?
Early bird savings now on
THE EARLY BIRD
IN-PERSON PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers.
$1,979
Early Bird pricing on for a limited time only
Why attend?
Learn
how America's life sciences landscape is evolving in areas such as innovation, commercialization and regulation
Engage
with C-suite executives responsible for the big decisions in areas such as funding, workforce development and strategic partnerships
Enjoy
the opportunity to network with peers and build relationships in a friendly but focused environment
Speakers include
The power of in-person networking
Supporting Partner
Contact Us
Speaking Opportunities
Ciaran Larkin
ciaran.larkin@ft.com
Sponsorship
Holly Watson-Steward
holly.watson-steward@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice